The survival outcomes of patients with resected non-small cell lung cancer differ according to EGFR mutations and the P21 expression

Lung Cancer

Volumn 57, Issue 1, 2007, Pages 96-102

  Na, Im II ^a   Rho, Jin Kyung ^a   Choi, Yun Jung ^a   Kim, Cheol Hyeon ^a   Park, Jong Ho ^a   Koh, Jae Soo ^a   Ryoo, Baek Yeol ^a   Yang, Sung Hyun ^a   Lee, Jae Cheol ^a  

^a Korea Cancer Center Hospital   (South Korea)

Author keywords

EGFR mutation; Lung cancer; p21

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; P21 ACTIVATED KINASE;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; EXON; FEMALE; GENE DELETION; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SMOKING; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CYCLIN-DEPENDENT KINASE INHIBITOR P21; EXONS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, DIRECT; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROGNOSIS; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEQUENCE ANALYSIS, DNA; SEX FACTORS; SURVIVAL ANALYSIS;

EID: 34249679620     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.01.027     Document Type: Article

References (35)

1. Hirsch F.R., Varella-Garcia M., Bunn Jr. P.A., Di Maria M.V., Veve R., Bremmes R.M., et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21 (2003) 3798-3807
2. Selvaggi G., Novello S., Torri V., Leonardo E., De Giuli P., Borasio P., et al. Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. Ann Oncol 15 (2004) 28-32
3. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 (2004) 2129-2139
4. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
5. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101 (2004) 13306-13311
6. Shigematsu H., Lin L., Takahashi T., Nomura M., Suzuki M., Wistuba I.I., et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97 (2005) 339-346
7. Tsao M.S., Sakurada A., Cutz J.C., Zhu C.Q., Kamel-Reid S., Squire J., et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 353 (2005) 133-144
8. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353 (2005) 123-132
9. Eberhard D.A., Johnson B.E., Amler L.C., Goddard A.D., Heldens S.L., Herbst R.S., et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23 (2005) 5900-5909
10. Riely G.J., Pao W., Pham D., Li A.R., Rizvi N., Venkatraman E.S., et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 12 (2006) 839-844
11. Xiong Y., Hannon G.J., Zhang H., Casso D., Kobayashi R., and Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 366 (1993) 701-704
12. Harper J.W., Adami G.R., Wei N., Keyomarsi K., and Elledge S.J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75 (1993) 805-816
13. Johnson M., Dimitrov D., Vojta P.J., Barrett J.C., Noda A., Pereira-Smith O.M., et al. Evidence for a p53-independent pathway for upregulation of SDI1/CIP1/WAF1/p21 RNA in human cells. Mol Carcinog 11 (1994) 59-64
14. Shoji T., Tanaka F., Takata T., Yanagihara K., Otake Y., Hanaoka N., et al. Clinical significance of p21 expression in non-small-cell lung cancer. J Clin Oncol 20 (2002) 3865-3871
15. Sato K., Nagao T., Iwasaki T., Nishihira Y., and Fukami Y. Src-dependent phosphorylation of the EGF receptor Tyr-845 mediates Stat-p21waf1 pathway in A431 cells. Genes Cells 8 (2003) 995-1003
16. 3-induced c-Src/EGFR/ERK signaling is via Sp1 binding sites to stimulate p21WAF1/CIP1 expression in human epidermoid carcinoma A431 cells. Cell Signal 18 (2006) 244-255
17. Di Gennaro E., Barbarino M., Bruzzese F., De Lorenzo S., Caraglia M., Abbruzzese A., et al. Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells. J Cell Physiol 195 (2003) 139-150
18. Brambilla E., Travis W.D., Colby T.V., Corrin B., and Shimosato Y. The new World Health Organization classification of lung tumours. Eur Respir J 18 (2001) 1059-1068
19. Ebright M.I., Zakowski M.F., Martin J., Venkatraman E.S., Miller V.A., Bains M.S., et al. Clinical pattern and pathologic stage but not histologic features predict outcome for bronchioloalveolar carcinoma. Ann Thorac Surg 74 (2002) 1640-1646 [discussion 1646-1647]
20. Miller V.A., Kris M.G., Shah N., Patel J., Azzoli C., Gomez J., et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 22 (2004) 1103-1109
21. Pan C.C., Chen P.C., and Chiang H. An easy method for manual construction of high-density tissue arrays. Appl Immunohistochem Mol Morphol 12 (2004) 370-372
22. Han S.W., Kim T.Y., Hwang P.G., Jeong S., Kim J., Choi I.S., et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 23 (2005) 2493-2501
23. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
24. Cox D.R. Regression models and life-tables. J R Stat Soc [B] 44 (1972) 793-797
25. Gartel A.L., and Radhakrishnan S.K. Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res 65 (2005) 3980-3985
26. Ogino S., Meyerhardt J.A., Cantor M., Brahmandam M., Clark J.W., Namgyal C., et al. Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. Clin Cancer Res 11 (2005) 6650-6656
27. Xia W., Chen J.S., Zhou X., Sun P.R., Lee D.F., Liao Y., et al. Phosphorylation/cytoplasmic localization of p21Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients. Clin Cancer Res 10 (2004) 3815-3824
28. Huang S., Shu L., Dilling M.B., Easton J., Harwood F.C., Ichijo H., et al. Sustained activation of the JNK cascade and rapamycin-induced apoptosis are suppressed by p53/p21(Cip1). Mol Cell 11 (2003) 1491-1501
29. Kosaka T., Yatabe Y., Endoh H., Kuwano H., Takahashi T., and Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 64 (2004) 8919-8923
30. Alexiou C., Onyeaka C.V., Beggs D., Akar R., Beggs L., Salama F.D., et al. Do women live longer following lung resection for carcinoma?. Eur J Cardiothorac Surg 21 (2002) 319-325
31. Bouchardy C., Fioretta G., De Perrot M., Obradovic M., and Spiliopoulos A. Determinants of long term survival after surgery for cancer of the lung: a population-based study. Cancer 86 (1999) 2229-2237
32. Ferguson M.K., Wang J., Hoffman P.C., Haraf D.J., Olak J., Masters G.A., et al. Sex-associated differences in survival of patients undergoing resection for lung cancer. Ann Thorac Surg 69 (2000) 245-249
33. Gazdar A.F., Shigematsu H., Herz J., and Minna J.D. Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers?. Trends Mol Med 10 (2004) 481-486
34. Huse M., and Kuriyan J. The conformational plasticity of protein kinases. Cell 109 (2002) 275-282
35. Sasaki H., Shimizu S., Endo K., Takada M., Kawahara M., Tanaka H., et al. EGFR and erbB2 mutation status in Japanese lung cancer patients. Int J Cancer 118 (2006) 180-184